TWT-202
Phase 1b/2 Clinical Study of the Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Profiles of CFI-400945 as a Single Agent or in Combination With Azacitidine or Decitabine in Patients With AML, MDS or CMML
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1/2
- Enrollment
- 72 patients (estimated)
- Sponsors
- Treadwell Therapeutics, Inc
- Tags
- Antimetabolites, Chemotherapy, Hypomethylating Agents (HMA), PLK4 Inhibitor
- Trial Type
- Treatment
- Last Update
- 1 month ago
- SparkCures ID
- 1566
- NCT Identifier
- NCT04730258
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.